GRI Bio Inc 2026年季度报告

FORM10-Q____________________________________ (Mark One) QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedJune 30, 2026 TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934 (Exact Name of Registrant as Specified in its Charter) 82-4369909(I.R.S. EmployerIdentification No.) Delaware(State or other jurisdiction ofincorporation or organization) 2223 Avenida de la Playa, #208La Jolla, CA 92037 (Address of principal executive offices, including zip code) (619) 400-1170(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1)has filed all reports required to be filed by Section13 or 15(d)of the Securities ExchangeAct of 1934 during the preceding 12months (or for such shorter period that the registrant was required to file such reports), and (2)has been subjectto such filing requirements for the past 90days. YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule405 of Regulation S-T (§232.405 of this chapter) during the preceding 12months (or for such shorter period that the registrant was required tosubmit such files). YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section13(a)of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule12b-2 of the Exchange Act). Yes☐No As of August13, 2026, 2,186,115 shares of the Registrant’s common stock were outstanding. Table of Contents PARTI.FINANCIAL INFORMATION 3Item1.Financial Statements3Consolidated Balance Sheets as of June 30, 2026 (unaudited) and December 31, 20253Consolidated Statements of Operations (unaudited) for the three and six months ended June 30, 2026 and20254Consolidated Statements of Changes in Stockholders’ Equity (unaudited) for the six months ended June 30,2026 and 20255Consolidated Statements of Cash Flows (unaudited) for the six months ended June 30, 2026 and 20256Notes to Unaudited Interim Consolidated Financial Statements7Item2.Management’s Discussion and Analysis of Financial Condition and Results of Operations16Item3.Quantitative and Qualitative Disclosures About Market Risk24Item4.Controls and Procedures24PARTII.OTHER INFORMATION26Item1.Legal Proceedings26Item1A.Risk Factors26Item2.Unregistered Sales of Equity Securities and Use of Proceeds26Item3.Defaults Upon Senior Securities26Item4.Mine Safety Disclosures26Item5.Other Information26Item6.Exhibits28Signatures29 PART I—FINANCIAL INFORMATION GRI Bio, Inc.Consolidated Balance Sheets(in thousands, except share and per share amounts) GRI Bio, Inc.Consolidated Statements of Operations(in thousands, except share and per share amounts)(Unaudited) GRI Bio, Inc.Consolidated Statements of Changes in Stockholders’ Equity(in thousands, except shares)(Unaudited) GRI Bio, Inc.Consolidated Statements of Cash Flows(in thousands)(Unaudited) Six Months Ended June 30, GRI Bio, Inc.Notes to Unaudited Interim Consolidated Financial Statements(in thousands, except share and per share data) 1.ORGANIZATION AND DESCRIPTION OF BUSINESS GRI Bio, Inc. (GRI or the Company), based in La Jolla, CA, was incorporated in Delaware in May 2009, which is the date ofinception. GRI is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies thattarget serious diseases associated with dysregulated immune responses leading to inflammatory, fibrotic and autoimmune disorders.The Company’s goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patientssuffering from such diseases. The Company’s lead product candidate, GRI-0621, is an oral inhibitor of type 1 invariant Natural KillerT cells and is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis (IPF). TheCompany’s product candidate portfolio also includes GRI-0803 and a proprietary library of 500+ compounds. GRI-0803, the leadmolecule selected from the library, is a novel oral agonist of type 2 diverse Natural Killer T cells and is being developed for thetreatment of autoimmune disorders, with much of its preclinical work in Systemic Lupus Erythematosus Disease, or lupus, andmultiple sclerosis (MS). Recapitalization On February 21, 20